

# Actinium Pharmaceuticals Inc

03:28 17 Aug 2018

## Actinium Pharmaceuticals is misunderstood, says Oppenheimer

Analysts at Oppenheimer said on Thursday that shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) are significantly undervalued and should be rated as Outperform with a US\$5 price target because of catalysts in the next 12 to 18 months.

After attending a conference call Thursday, Oppenheimer said Actinium is approaching an inflection point on its outlook for a Phase 3 Sierra study of lomab-B for bone marrow transplant patients. The drug also has clinical trial support from the foremost bone marrow transplant centers in the US.

"We believe that investors are little aware of the furious pace at which ATNM is updating the lomab-B Phase 3 clinical trial, adding more Actimab-A indications and thoughtfully building out the management team," Oppenheimer analysts wrote in a research note. "We advise investors to carefully consider a misunderstood name."

**READ:** Actinium Pharmaceuticals unveils new clinical trial for leukemia with its treatment Actimab-A  
Oppenheimer assigned the value of lomab-B at US\$2.60/share, applying a 6x multiple to estimated 2025 sales of US\$323mIn. Along with other programs, the research analyst believes a target price of US\$5 is justified.

The key downside risks to the rating, Oppenheimer wrote, is the failure of the lomab-B study and another Phase 2 study for another drug to fight cancer.

Actinium Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options.

Shares were down 1.3% to US\$0.61 on Thursday.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

**Price:** 0.1896

**Market Cap:** \$31.23 m

### 1 Year Share Price Graph



April 2019    October 2019    April 2020

### Share Information

**Code:** ATNM

**Listing:** NYSE

**52 week**                      **High**                      **Low**  
   **0.5998**                      **0.1694**

**Sector:** Pharma & Biotech

**Website:** [www.actiniumpharma.com](http://www.actiniumpharma.com)

### Company Synopsis:

*Actinium is a leading biotechnology company developing targeted radioimmunotherapies for the treatment of cancer patients with unmet needs.*

[action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.